Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-108 RSV Vaccine in Healthy Adults
NCT06564194Phase 1Active, not recruiting
- Sponsor
- Immorna
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JCXH-108 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Immorna. Primary endpoints: Serious Adverse Event Frequency at 6 months, Injection site reaction at 30 days and 4 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
JCXH-108
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06564194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564194.